
|Slideshows|May 1, 2018
Initial Treatment and Cost of Care in Pulmonary Hypertension
Author(s)Veronica Hackethal MD
A new study finds that the first treatment chosen to treat PAH may help mitigate the burden of all-cause cost of care.
Advertisement
Treatment options for PAH are evloving, yet patient prognosis remains poor. PAH also confers a heavy ecomomic burden related to cost of drugs, hospitalizations, and comorobidities. There is research that suggests initial treatment with PAH-specific medications (vs combinations of agents) may decrease healthcare utilization. Could this strategy tranlsate into reduced overall healthcare costs to treat PAH?Â
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
4
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
5


























































